# Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

> **NCT00159250** · PHASE1,PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 7 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** AVI-4658 (PMO)

## Key facts

- **NCT ID:** NCT00159250
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-26
- **Primary completion:** 2008-12
- **Final completion:** 2009-03-31
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00159250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00159250, "Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00159250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*